日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reply to Harsanyi et al. Comment on "Hasan et al. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma. Clin. Pract. 2023, 13, 806-819"

回复 Harsanyi 等人的评论:“Hasan 等人,《肌层浸润性和非肌层浸润性常规尿路上皮膀胱癌中 p16、p53 和 Ki-67 表达的临床病理特征和免疫组织化学比较》,Clin. Pract. 2023, 13, 806-819”。

Hasan, Abdulkarim; Mohammed, Yasien; Basiony, Mostafa; Hanbazazh, Mehenaz; Samman, Abdulhadi; Abdelaleem, Mohamed Fayek; Nasr, Mohamed; Abozeid, Hesham; Mohamed, Hassan Ismail; Faisal, Mahmoud; Mohamed, Eslam; Ashmawy, Diaa; Tharwat, Mohamed; Morsi, Deaa Fekri; Farag, Abeer Said; Ahmed, Eman Mohamed; Aly, Noha M; Abdel-Hamied, Hala E; E A Salama, Doaa; Mandour, Essam

Evaluation of Some Prognostic Biomarkers in Human Papillomavirus-Related Multiphenotypic Sinonasal Carcinoma

人乳头瘤病毒相关多表型鼻窦癌中某些预后生物标志物的评价

Mohamed Ali Alabiad ,Warda M M Said ,Amal M A Adim ,Mohammed Alorini ,Amany Mohamed Shalaby ,Walaa Samy ,Shereen Elshorbagy ,Doaa Mandour ,Ibrahim Mohamed Saber ,Amar Ibrahim Omar Yahia ,Dina Ahmed Khairy

The Diagnostic and Prognostic Roles of Combined Expression of Novel Biomarkers in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma: An Immunohistochemical Study

新型生物标志物联合表达在肺腺癌和肺鳞状细胞癌中的诊断和预后作用:免疫组织化学研究

Mohamed Ali Alabiad, Ola A Harb, Mohamed Abozaid, Ahmed Embaby, Doaa Mandour, Rehab Hemeda, Amany Mohamed Shalaby